Tarsa Therapeutics developed TBRIA™, an oral formulation of calcitonin for postmenopausal osteoporosis. Rights to TBRIA have been acquired by R-Pharm JSC, whose US subsidiary is responsible for the continuing clinical development of TBRIA and subsequent regulatory submissions.
8 Penn Center
1628 John F Kennedy Boulevard
Phone / ContactT: +1 267 273 7940
F: +1 267 273 7950